Hematologic Oncology

Clinicians now have a new treatment to offer elderly patients with newly diagnosed acute myeloid leukemia who have comorbidities that preclude the use of intensive chemotherapy.

A study shows sequential monitoring of the WT1 mRNA is of value for the early detection of hematologic relapse in patients with AML in remission.

A patient’s minimal residual disease status may serve as a surrogate marker for outcome in clinical trials of chronic lymphocytic leukemia in patients with comorbidities.

Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome.

Testing patterns associated with the diagnosis and treatment of chronic lymphocytic leukemia have changed rapidly during the last decade.

The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

A new study has identified a clinically and biologically distinct subgroup of diffuse large B-cell lymphoma tumors.

A study looked at whether survivorship care plans were able to enhance patients' knowledge and adherence to physician recommendations.

Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.

Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.

Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.

Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.

Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.

Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.

Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.

This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.

Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia.

Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients.

A study investigates whether R-CHOP is a viable first-line treatment for patients with advanced follicular lymphoma.

A phase III study looks at the efficacy and safety of rituximab biosimilar CT-P10 in patients with follicular lymphoma.

Researchers discovered clinical and experimental evidence that calls into question the widely held notion that LSCs preferentially outlive chemotherapy.

Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.

The ground-breaking study, led by the Leukemia & Lymphoma Society, is evaluating several novel targeted therapies for acute myeloid leukemia.

In this article, we describe the considerations for the use of BTK inhibitors in lymphoid malignancies from the perspective of an oncology pharmacist.

Does patient race play a role in the efficacy of monoclonal antibodies in multiple myeloma?